Medicaments for chemotherapeutic treatment of disease

a chemotherapeutic and drug technology, applied in the direction of solution delivery, energy-modified materials, aerosol delivery, etc., can solve the problems of high incidence of disagreeable side effects, immune system suppression, and the difficulty of enhancing the specificity of the drug for tissues to be treated,

Inactive Publication Date: 2003-07-17
PROVECTUS PHARMATECH
View PDF6 Cites 39 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, most chemotherapeutic agents presently available offer limited specificity for such tissue, resulting in a high incidence of disagreeable side-effects, such as immune system suppression, nausea, and hair loss.
While tremendous strides have been made in an effort to reduce or mitigate such side-effects, there still continues to be great difficulty in enhancement of specificity of the drug for tissues to be treated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicaments for chemotherapeutic treatment of disease
  • Medicaments for chemotherapeutic treatment of disease
  • Medicaments for chemotherapeutic treatment of disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The present invention is directed to new chemotherapeutic medicaments and certain medical uses of such chemotherapeutic medicaments, and methods for chemotherapeutic treatment using such medicaments, for treatment of human or animal tissue, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The inventors of the present invention have discovered that such halogenated xanthenes, as discussed in more detail infra, exhibit desirable chemotherapeutic effects when applied to or otherwise delivered to certain human or animal tissues. The desirable effects include reduction or elimination of disease or diseased tissue or other undesirable conditions, including eradication of cancerous or pre-cancerous tumors and infectious agents. The treatment is applicable to a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

Description

[0001] This application is based on provisional application U.S. Ser. No. 60 / 218,464 filed Jul. 14, 2000 and is a continuation-in-part of U.S. Ser. No. 09 / 130,041, filed on Aug. 6, 1998; U.S. Ser. No. 60 / 149,015, filed on Aug. 13, 1999 and U.S. Ser. No. 09 / 635,276 filed on Aug. 9, 2000; and U.S. Ser. No. 60 / 191,803, filed on Mar. 24, 2000 and U.S. Ser. No. 09 / 799,785 filed on Mar. 6, 2001, which are herein incorporated by reference in their entirety.[0002] The present invention is related to certain chemotherapeutic medicaments and methods for treatment of human or animal tissue using chemotherapy.[0003] Chemotherapy was developed to treat cancer and other disease with the promise of limiting the invasiveness of the therapeutic intervention. Ideally in the practice of chemotherapy, chemical agents that afford selective toxicity to diseased or otherwise undesirable tissue are administered to a patient. Frequently, these agents are administered systemically, with the expectation that ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D311/82A61B17/22A61F7/00A61K9/00A61K9/06A61K9/08A61K9/12A61K31/352A61K41/00A61K47/10A61K47/12A61K47/20A61K47/48A61N5/06A61P31/00A61P35/00A61P43/00
CPCA61B2017/22062Y10T436/193333A61F7/00A61K9/0014A61K9/0019A61K31/352A61K41/0057A61K47/10A61K47/12A61K47/20A61N5/0601A61N5/062C07D311/82A61K41/0071A61B2017/22087A61P17/06A61P31/00A61P35/00A61P43/00Y02A50/30
Inventor DEES, H. CRAIGSCOTT, TIMOTHY C.
Owner PROVECTUS PHARMATECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products